In vivo effects of cyclosporin A on murine B-cells responding to type III pneumococcal polysaccharide

Sozzani, Silvano; Sironi, Marina; Magistrelli, M.; Luini, Walter; Spreafico, F.; Vecchi, Annunciata

doi:10.1016/0192-0561(90)90016-g

International Journal of Immunopharmacology

1990

DOI: 10.1016/0192-0561(90)90016-g

|View full text |Cite

In vivo effects of cyclosporin A on murine B-cells responding to type III pneumococcal polysaccharide

Silvano Sozzani

Marina Sironi

M. Magistrelli

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1991

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Immune monitoring of heart transplant patients receiving either one or two cycles of OKT3 prophylaxis. Induced anti‐idiotypic and anti‐isotypic anti‐OKT3 antibodies do not prohibit depletion of peripheral T cells due to second OKT3 treatment

Hesse,

Heyse,

Stalk

et al. 1991

Clinical Transplantation

View full text Add to dashboard Cite

24 heart transplant recipients were treated with OKT3 together with azathioprine for 7 days as a rejection prophylaxis. The plasma OKT3 concentration ranged from 280 to 1600 ng/ml. During treatment the T cells in peripheral blood disappeared but returned modulated without TcR‐α/β‐chains and with low CD3 expression. Antimurine antibodies were induced and median IgG antimurine antibody concentrations increased from 9.6 mg/l pretransplant to 52.1 mg/l as measured by ELISA. In 13 out of 24 patients, anti‐idiotypic antibodies were present at a level that caused over 50% inhibition of OKT3 binding to T cells. The extent of inhibition was positively correlated with the increase in IgG antimurine antibody levels, both in relative (> 3 times pre‐transplant level, p < 0.05) and in absolute terms (more than 50 mg/l, p < 0.001). In 9 patients, who received two prophylactic courses of OKT3, we found a decrease in anti‐OKT3 antibody levels after the second course of OKT3 which can be caused by the additional cyclosporin A (CsA) immune suppression. The second course also resulted in a rapid depletion of circulating functional T cells despite the presence of anti‐OKT3 antibodies generated after the first course.

show abstract

Immune monitoring of heart transplant patients receiving either one or two cycles of OKT3 prophylaxis. Induced anti‐idiotypic and anti‐isotypic anti‐OKT3 antibodies do not prohibit depletion of peripheral T cells due to second OKT3 treatment

Hesse,

Heyse,

Stalk

et al. 1991

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

In vivo effects of cyclosporin A on murine B-cells responding to type III pneumococcal polysaccharide

Cited by 1 publication

References 26 publications

Immune monitoring of heart transplant patients receiving either one or two cycles of OKT3 prophylaxis. Induced anti‐idiotypic and anti‐isotypic anti‐OKT3 antibodies do not prohibit depletion of peripheral T cells due to second OKT3 treatment

Immune monitoring of heart transplant patients receiving either one or two cycles of OKT3 prophylaxis. Induced anti‐idiotypic and anti‐isotypic anti‐OKT3 antibodies do not prohibit depletion of peripheral T cells due to second OKT3 treatment

Contact Info

Product

Resources

About